Evidence map›Paper›PMID 30925125›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial.

Kazuhiro Yoshida, Yasuhiro Kodera, Mitsugu Kochi, Wataru Ichikawa, Yoshihiro Kakeji, Takeshi Sano, Narutoshi Nagao, Masazumi Takahashi, Akinori Takagane, Takuya Watanabe and 10 more

Open access · hybridAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 266 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
266citing papers in PubMed, 9 pooled it
35.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

266 citing papers in PubMed, 9 syntheses or guidelines pooled it, 382 citations in OpenAlex.

  1. Japanese gastric cancer treatment guidelines 2025 (7th edition).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Guideline
  2. Pooled it
  3. SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Guideline
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Trial
  14. Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: short-term outcomes of a multicenter, phase II study (OGSG1902).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023
    Trial
  20. Trial

206 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 17 institutions in 1 country.

Kazuhiro Yoshida1 Gifu University, Gifu, Japan.
Yasuhiro Kodera2 Nagoya University, Nagoya, Japan.
Mitsugu Kochi3 Nihon University Itabashi Hospital, Tokyo, Japan.
Wataru Ichikawa4 Showa University Fujigaoka Hospital, Yokohama, Japan.
Yoshihiro Kakeji5 Kobe University Graduate School of Medicine, Kobe, Japan.
Takeshi Sano6 Cancer Institute Hospital, Tokyo, Japan.
Narutoshi Nagao7 Gifu Prefectural General Medical Center, Gifu, Japan.
Masazumi Takahashi8 Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
Akinori Takagane9 Hakodate Goryoukaku Hospital, Hakodate, Japan.
Takuya Watanabe10 Konan Kosei Hospital, Konan, Japan.
Masahide Kaji11 Toyama Prefectural Central Hospital, Toyama, Japan.
Hiroshi Okitsu12 Tokushima Red Cross Hospital, Komatsushima, Japan.
Takashi Nomura13 Yamagata Prefectural Central Hospital, Yamagata, Japan.
Takanori Matsui14 Aichi Cancer Center Aichi Hospital, Okazaki, Japan.
Takaki Yoshikawa15 Kanagawa Cancer Center, Yokohama, Japan.
Jin Matsuyama16 Yao Municipal Hospital, Yao, Japan.
Makoto Yamada17 Gifu Municipal Hospital, Gifu, Japan.
Seiji Ito18 Aichi Cancer Center Hospital, Nagoya, Japan.
Masahiro Takeuchi19 Kitasato University, Tokyo, Japan.
Masashi Fujii3 Nihon University Itabashi Hospital, Tokyo, Japan.
Aichi Cancer Center · JPNihon University Itabashi Hospital · JPGifu Municipal Hospital · JPGifu Prefectural General Medical Center · JPGifu University · JPHakodate National Hospital · JPKanagawa Cancer CenterKitasato University · JPKobe University · JPKomatsu (Japan) · JPKonan Kosei Hospital · JPNagoya University · JPShowa University Fujigaoka Hospital · JPThe Cancer Institute Hospital · JPToyama Prefectural Central Hospital · JPYamagata Prefectural Central Hospital · JPYokohama Municipal Citizen's Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeS-1 is a standard postoperative adjuvant chemotherapy for patients with stage II or III gastric cancer in Asia. Neoadjuvant or perioperative strategies dominate in Western countries, and docetaxel has recently shown significant survival benefits when combined with other standard regimens in advanced cancer and perioperative settings. PATIENTS AND

methodsThis randomized phase III study was designed to prove the superiority of postoperative S-1 plus docetaxel over S-1 alone for R0 resection of pathologic stage III gastric cancer. The sample size of 1,100 patients was necessary to detect a 7% increase in 3-year relapse-free survival as the primary end point (hazard ratio, 0.78; 2-sided α = .05; β = .2).

resultsThe second interim analysis was conducted when the number of events reached 216 among 915 enrolled patients (median follow-up, 12.5 months). Analysis demonstrated the superiority of S-1 plus docetaxel (66%) to S-1 (50%) for 3-year relapse-free survival (hazard ratio, 0.632; 99.99% CI, 0.400 to 0.998; stratified log-rank test,

conclusionAddition of docetaxel to S-1 is effective with few safety concerns in patients with stage III gastric cancer. The present findings may also be applicable in countries in which perioperative adjuvant chemotherapy or chemoradiation is not standard.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDocetaxelDrug CombinationsFemaleGastrectomyHumansMaleMedication AdherenceMiddle AgedNeoplasm StagingOxonic AcidPostoperative CareStomach NeoplasmsDocetaxelDrug CombinationsOxonic AcidS 1 (combination)Tegafur

Identifiers

PMID30925125
PMCPMC6524985
OpenAlexW2932398125

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.